Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AxoGen, Inc. (AXGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
9.28-0.04 (-0.43%)
At close: 04:00PM EST
9.01 -0.27 (-2.91%)
After hours: 06:48PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close9.32
Open9.29
Bid9.01 x 800
Ask9.35 x 900
Day's Range9.07 - 9.42
52 Week Range6.87 - 13.66
Volume215,953
Avg. Volume222,557
Market Cap392.42M
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.77
Earnings DateMar 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 27, 2010
1y Target Est17.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AXGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AxoGen, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/07/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    14 hours agoArgus Research
View more
  • GlobeNewswire

    Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

    ALACHUA, Fla. and TAMPA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2022 revenue. Preliminary Unaudited Fourth Quarter and Year-End Performance and Business Highlights Fourth quarter revenue is expected to be approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the imp

  • GlobeNewswire

    Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits

    Study concluded allograft and autograft repairs delivered significantly better rates of meaningful sensory recovery in short gaps as compared to conduit repairs in a systematic meta-analysis including over 1,500 nerve repairs across 35 studiesALACHUA, Fla. and TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the independent publication of a comprehen

  • GlobeNewswire

    Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference

    ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan 41st Annual Healthcare Conference in San Francisco. The presentation is scheduled for Thursday, January 12, 2023 at 9:45 a.m. PST (12:45 p.m. EST). The presentation will be webcast live and accessible thro

Advertisement
Advertisement